Hyperkalemia: Recognize, Stabilize, Shift, Remove, Reassess

Visual reference

Browse the visual reference library · Download lesson Markdown

Acute hyperkalemia: potassium and the ECG

Read the level and the tracing together

The UK Kidney Association classifies potassium 5.5–5.9 mmol/L as mild, 6.0–6.4 as moderate and ≥6.5 as severe hyperkalemia. The tracing can show peaked T waves, PR prolongation, P-wave flattening or disappearance, QRS widening and eventually QRS–T fusion. These are illustrative patterns, not potassium-specific thresholds or a dependable sequence.

Treat electrical toxicity promptly

A normal ECG does not exclude severe hyperkalemia. Interpret the potassium trend, symptoms, kidney function and ECG together. With convincing ECG toxicity, protect the myocardium with IV calcium while arranging potassium redistribution and removal. Calcium does not lower potassium. The clean repeat specimen and definitive treatment proceed alongside emergency care.

Supporting evidence

• UK Kidney Association: hyperkalemia guideline, updated July 2026
• KDIGO conference summary: acute hyperkalemia

Apply this framework in the Day 1 teaching collection →

Recognize risk before choosing a treatment

Hyperkalemia can cause lethal conduction disturbance. Assess symptoms, the potassium concentration and trend, kidney function, the clinical setting, and the ECG. A normal ECG does not reliably exclude danger. Severe hyperkalemia, concerning ECG changes, or clinical instability requires urgent monitored assessment [1,2].

Check for sampling artifact when appropriate, but do not delay treatment of a convincing emergency while awaiting a repeat sample. Hemolysis, difficult collection, or marked blood-cell abnormalities can produce misleading results. Interpret laboratory and point-of-care results in context [1,3].

Find the mechanism and reversible contributors

Consider impaired kidney excretion, reduced distal sodium delivery or aldosterone effect, cellular potassium release, and shifts out of cells. Review potassium supplements, salt substitutes, renin-angiotensin system drugs, potassium-sparing diuretics, NSAIDs, trimethoprim, and other relevant exposures [2].

AKI, advanced CKD, tissue injury, and insulin deficiency can coexist. Dietary intake alone is rarely the complete explanation when kidney handling is impaired. Treat the cause and reconsider long-term medication plans after immediate danger is controlled.

Protect the myocardium when indicated

Treat urgent threats while you evaluate

Read the urgent-care framework and evidence →

Intravenous calcium is used for hyperkalemia-associated ECG changes or other indications defined by the emergency protocol. Calcium stabilizes the myocardium; it does not remove potassium. Reassess the ECG and clinical response, and follow local formulation, administration, and repeat-dose guidance [1,3].

Stabilization, potassium shifting, removal, and cause assessment may need to proceed in parallel. A rigid sequence that delays emergency treatment for a bladder catheter is unsafe.

Acute hyperkalemia: buy time, then remove potassium

Calcium: prioritize conduction toxicity

Hyperkalemia-associated QRS widening, a sine-wave pattern, dangerous bradycardia or ventricular arrhythmia, and suspected hyperkalemic arrest are urgent reasons for IV calcium. Isolated peaked T waves are less specific and were not associated with short-term adverse events in one observational study; they are not equivalent to QRS widening. However, calcium guidance differs: UKKA includes isolated hyperkalemic peaked T waves. Teach the distinction without a blanket rule to withhold calcium. Use the emergency protocol and the whole clinical picture.

Calcium buys a short interval

The ECG effect begins in about 1–3 minutes and lasts roughly 30–60 minutes. Reassess promptly; persistent or recurrent toxicity may require repeat calcium while shifting and removal proceed. Calcium does not reduce serum or total-body potassium. Formulations are not dose-equivalent: calcium chloride contains about three times the elemental calcium per equal volume of a 10% solution. Follow the local formulation, dose, route and repeat-dose protocol.

Insulin plus dextrose: an early shift with a later glucose risk

IV regular insulin begins lowering potassium in about 15 minutes, with peak effect around 30–60 minutes. The shift may persist for 4–6 hours, but potassium can begin rebounding earlier. Dextrose supports blood glucose; it does not make the insulin effect harmless or guarantee six hours of protection. Check glucose before treatment and frequently for at least six hours afterward, extending monitoring after repeat doses or in high-risk patients. Kidney failure increases delayed hypoglycemia risk.

Albuterol: a hyperkalemia dose, not an ordinary bronchodilator treatment

The studied adult nebulized dose is 10–20 mg total, substantially more than a routine 2.5 mg nebulizer treatment. Specify total dose and delivery time with respiratory therapy under the local protocol. A rate such as 20 mg/hour is not interchangeable with a total 20 mg dose and should not be taught as an indefinite standard infusion. Potassium lowering generally begins by about 30 minutes and lasts at least two hours, commonly about 2–4 hours; some responses last longer. Response varies, so use it as an adjunct, not sole therapy for severe hyperkalemia. Watch for tachycardia, tremor and ischemic symptoms.

Bicarbonate: do not assign it a dependable potassium clock

IV bicarbonate is not routinely effective as acute hyperkalemia monotherapy. It may be useful when clinically important metabolic acidosis supplies a separate indication, with attention to sodium, volume and ventilation. The magnitude, onset and duration of potassium lowering are inconsistent; a fixed two-hour or six-hour rescue window would be misleading. In a small crossover study of hemodialysis patients, bicarbonate alone did not lower potassium during the first hour.

Recheck the patient, not just the first improved number

Continue ECG monitoring when indicated, repeat potassium early after treatment and again as the shift wears off, and track glucose separately. A useful monitored framework checks potassium around one and two hours, then four and six hours, with earlier or additional testing for instability or a changing trajectory. Calcium can wear off before dialysis starts; shifted potassium remains in the body. Reassess and bridge until actual removal provides sustained control.

Shift potassium into cells and monitor glucose

Insulin with appropriate glucose support temporarily shifts potassium into cells. Monitor glucose before and repeatedly after treatment because hypoglycemia can be delayed, particularly with kidney impairment. Nebulized beta-2 agonists can provide an additional shift, but response varies and they should not be relied on alone for severe hyperkalemia [1,3].

Bicarbonate is not a reliable stand-alone potassium treatment in every patient. Its role depends on acid-base status, sodium load, and the clinical setting. Do not predict a fixed potassium change from a change in pH [3].

Arrange potassium removal

Temporizing shifts do not eliminate total-body potassium. Plans for removal and repeated assessment are essential when ongoing production or impaired excretion persists [1,4].

Hyperkalemia: remove potassium while the clock runs

Lokelma: early gut binding is useful, but it is not immediate rescue

Sodium zirconium cyclosilicate (SZC; Lokelma) binds potassium within the gastrointestinal lumen, including both the small and large intestine, and increases fecal potassium loss. With the studied initial regimen of 10 g three times daily, serum potassium reduction was observed at one hour and continued over the following 48 hours. That is an onset signal, not a guarantee of adequate correction at one hour. The US label states that it should not be used as emergency treatment for life-threatening hyperkalemia. It may be an adjunct while effective emergency treatment and removal are arranged; do not substitute it for calcium, shifting treatment or urgent dialysis. Consider bowel function, sodium-related edema and separation from interacting oral medications.

Why SPS is a poor emergency choice

Sodium polystyrene sulfonate (SPS; Kayexalate) has delayed and unpredictable potassium lowering, often taking hours to days, with limited evidence for rapid emergency benefit. Its labeling includes serious gastrointestinal injury, including ischemia, necrosis and perforation; sorbitol adds risk. It also supplies sodium and can affect other medications. It is not a dependable emergency bridge and should not be the reason to defer dialysis. This does not imply that every use of SPS is prohibited; it explains why it is a poor choice for this unstable case.

Dialysis starts a process, not an instantaneous result

Call the dialysis team early and establish whether usable access is already present. Staff mobilization, assessment, an access procedure when necessary, machine safety checks, dialyzer and circuit priming, and connection all precede clearance. Readiness can take tens of minutes to hours, depending on local resources; no universal machine-setup time is defensible. Ask for the actual estimated start time and escalate a delay that exceeds the patient's clinical tolerance. Potassium removal begins when treatment runs, not when the order is entered. Continue temporizing treatment and monitoring during preparation; check for post-dialysis rebound.

Still making urine? Look for a reversible drainage problem

Residual urine output makes a urinary contribution possible, but urine volume does not measure potassium clearance. If retention, a blocked catheter or obstructive AKI is plausible, assess bladder volume and catheter patency and decompress retention when indicated. A Foley can relieve lower-tract obstruction and measure output when those indications exist. It is not a universal first step and does not treat upper-tract obstruction by itself. Useful renal function and appropriate perfusion are still needed for potassium excretion; a loop diuretic may assist selected patients. Do not delay cardiac protection or urgent dialysis while waiting for a urinary response. After decompression, monitor for post-obstructive diuresis, volume loss and electrolyte changes.

Apply the parallel plan to Case 1

Mr. Hartman has a widened QRS, missed dialysis, pulmonary edema and insufficient potassium clearance despite residual urine. Protect the heart, shift potassium, call for urgent dialysis, and consider an appropriate gut binder while the team prepares. Assess retention if the history, examination or low output suggests it. An early potassium fall after insulin does not remove the body load or resolve pulmonary edema. State when each treatment started, when its effect may fade, and when the next potassium, ECG and glucose assessment is due.

Assess urinary obstruction without delaying emergency care

Bladder assessment and catheterization are appropriate when retention or catheter malfunction is suspected. Decompression treats a reversible cause of obstructive kidney injury. A Foley catheter is not a universal first treatment for hyperkalemia, and there is no dependable fixed potassium reduction from catheter placement alone [5].

Do not postpone cardiac stabilization, shifting therapy, or urgent dialysis while waiting for urine output to improve. After decompression, monitor urine output, volume status, and electrolytes because post-obstructive diuresis can cause further disturbances [5].

Reassess for response, hypoglycemia, and rebound

Repeat potassium at intervals appropriate to severity and treatment, monitor ECG and glucose as indicated, and evaluate ongoing potassium release and actual removal. An initial fall after insulin does not prove the emergency is over. Rebound may occur after the shift wears off or after dialysis [1,4].

Disposition depends on sustained response, the underlying cause, kidney function, and a safe monitoring plan. Do not use a calculator-generated expected reduction as evidence that a patient is ready for discharge.

Apply the framework: a synthetic case

A patient with AKI has severe hyperkalemia, weakness, and ECG changes. A bladder scan also suggests retention. Explain why these findings require simultaneous emergency treatment and obstruction assessment, rather than “Foley first” followed by waiting several hours.

References

1. Lindner G, et al. Acute hyperkalemia in the emergency department: a summary from a KDIGO conference. 2020. PubMed 32852924
2. Clase CM, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a KDIGO Controversies Conference. 2020. PubMed 31706619
3. An Evidence-Based Narrative Review of the Emergency Department Management of Acute Hyperkalemia. 2021. PubMed 33423833
4. Hyperkalemia management in the emergency department: An expert panel consensus. 2021. PubMed 34632453
5. Yaxley J, Yaxley W. Obstructive uropathy — acute and chronic medical management. 2023. PubMed 36704657